Celltrion
Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Jung Jin Seo, is the richest person in South Korea.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Blitzima | Rituximab | 2017-07-13 | ||
| Herzuma | Trastuzumab | 2018-12-14 | ||
| Inflectra | Infliximab | 2016-04-05 | ||
| Memantine | Memantine | 2015-09-04 | 2025-2029 | |
| Regkirona | Regdanvimab | 2021-11-12 | — | |
| Remsima | Infliximab | 2013-09-10 | ||
| Ritemvia | Rituximab | 2017-07-13 | ||
| Rituzena (previously tuxella) | Rituximab | 2017-07-13 | ||
| Truxima | Rituximab | 2018-11-28 | ||
| Vegzelma | Bevacizumab | 2022-09-27 | ||
| Yuflyma | Adalimumab | 2023-05-23 |
1
2
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use